Pelthos Therapeutics (PTHS) Q3 2026 earnings review
Pelthos adds insurance coverage, but Zelsuvmi sales stall sequentially
Pelthos Therapeutics, a maker of prescription skin treatments, saw its flagship Zelsuvmi gel plateau after three quarters of rapid launch growth. Chief executive Scott Plesha highlighted $15 million in product revenue, more than double last year's launch quarter, but sales slipped 1% from the second quarter as larger insurer rebates offset a 4% rise in dispensed units. Operating cash losses excluding one-offs stayed near $6 million, and the company borrowed an extra $10 million in October while agreeing to merge with gene-therapy developer Castle Creek Biosciences.
| Zelsuvmi net product sales | $15.2M -1% from last quarter (+114% from a year ago) |
|---|---|
| Units dispensed | 12,384 +4% from last quarter |
| Adjusted EBITDA loss | -$5.6M -$5.7M last quarter |
| Cash plus October loan draw | $27.7M by our math; launch plans unchanged |
⚖️ Verdict: 🔴 Bearish
The story got worse because Zelsuvmi revenue flattened before the company could reach cash-flow breakeven. By our math, net revenue per dispensed unit fell 5% from last quarter to $1,228 as new payer discounts took hold, leaving trailing twelve-month sales nearly $20 million short of the threshold required to unlock the final $10 million loan tranche. One positive: reported gross margin reached 89% as old acquisition inventory charges faded.
The question now is whether adding 27 million newly insured commercial lives will restart Zelsuvmi growth fast enough to cut cash burn before the Castle Creek merger closes in early 2027. Either the new pharmacy coverage drives a fourth-quarter jump in prescriptions, or deeper rebates hold quarterly sales near $15 million while the incoming gene-therapy pipeline adds clinical trial costs. Fourth-quarter dispensed units and merger financing details will settle it.
🐂 Bull Case
Prescriber Breadth and Payer Access Expanded Again
Pelthos sells Zelsuvmi, the first prescription gel approved for home use to treat molluscum contagiosum, a viral skin infection. To grow the launch, the skin-drug maker needs more doctors writing prescriptions and more insurers paying for them. Both measures moved up in the third quarter.
- Active prescribers: 4,942 doctors dispensed the gel in the third quarter, up 8.1% from 4,571 in the second quarter
- New commercial coverage: a major pharmacy benefit manager added 24 million lives, and a regional health plan added 3 million
- Total insurance reach: 127 million commercial lives (69% of that market) and over 70 million Medicaid lives (100% of that market)
Wider insurance coverage matters because doctors prescribe a skin gel more readily when families do not face rejections at the pharmacy counter.
What to watch: dispensed prescription units in the fourth quarter. A rebound in sequential unit growth will show whether the 27 million newly covered commercial lives turn into filled prescriptions.
Gross Margin Reached 89% as Inventory Charges Faded
When Pelthos merged with LNHC in July 2025, accounting rules required it to mark up the value of Zelsuvmi inventory on hand. As that stock sells, the non-cash markup flows through cost of goods sold, the cost of making the product, and depresses reported gross margin.
In the third quarter, cost of goods sold dropped to 10.8% of total revenue from 23.1% in the second quarter, lifting reported gross margin by 12.4 percentage points to 89.2%. The non-cash inventory markup fell to $0.8 million from $2.3 million, and the drug maker avoided the $0.9 million batch write-off that hit the prior quarter. Excluding those accounting items, underlying gross margin was 94.6% by our math.
What to watch: the remaining inventory markup in the fourth quarter. Once the company finishes using its marked-up active ingredient, reported gross margin will match its cash production cost.
New $10 Million Loan Extends Cash Runway
Cash burn has been a central risk for Pelthos because it is funding a national dermatology sales force before its first drug reaches profitability. Cash on hand fell by $6.5 million during the third quarter to $17.7 million at the end of September.
On October 30, the company amended its loan agreement with Horizon Technology Finance and drew an extra $10.0 million, bringing total borrowings under the facility to $40.0 million. By our math, that loan lifted cash to $27.7 million before October operating spend, giving the business roughly four quarters of funding at the third-quarter burn pace.
What to watch: fourth-quarter cash outflow in the annual filing. A smaller cash drop will show whether Zelsuvmi collections can fund the planned first-quarter relaunch of Xepi, its impetigo cream.
🐻 Bear Case
Volume Growth Slowed and Revenue Per Unit Fell
"Zelsuvmi delivered another solid quarter, generating net product revenue of $15.2 million," chief executive Scott Plesha said. While sales more than doubled from last year's launch quarter — and rose about 270% by our math after stripping out roughly $3 million of initial pharmacy stocking — sequential momentum stalled.
Net product revenue slipped 1.3% from the second quarter's $15.4 million even though dispensed units rose 3.9% to 12,384. Unit growth slowed from 47.5% in the second quarter, adding only 459 new units sequentially. By our math, realized net revenue per dispensed unit fell 5.0% from last quarter to $1,228, down from $1,293 in the second quarter and $1,441 in the fourth quarter of 2025.
That drop happened because signing new pharmacy benefit managers requires larger rebates. The company expects "a slight increase in gross-to-net deductions, and improving net revenue per unit over time" as the new coverage takes effect, though the press release did not print the exact third-quarter discount rate.
What to watch: realized net revenue per dispensed unit in the fourth quarter. A further drop below $1,200 would show that rebates for the new 24-million-life contract are outweighing volume gains.
Cash Burn Continues and Stockholders' Deficit Widened
Late last year, management talked about reaching cash-flow breakeven by the end of 2026 and hitting $175 million in peak annual Zelsuvmi sales in 2028. For a third straight quarter, the release omitted both targets, and operating losses stopped shrinking.
- Adjusted EBITDA loss (operating cash loss excluding one-offs): $5.6 million, barely changed from $5.7 million in the second quarter
- Stockholders' deficit: widened to $6.2 million at September 30 from $1.5 million in June, compared with $38.9 million of positive equity at year-end 2025
- Remaining $10 million Horizon loan tranche: requires $70.0 million in trailing twelve-month net revenue before the end of 2027, against $50.4 million over the last four quarters by our math
Because Zelsuvmi revenue flattened at $15.2 million this quarter, Pelthos remains nearly $20 million short of the revenue milestone required to unlock that final loan tranche.
What to watch: Adjusted EBITDA in the fourth quarter. If the quarterly loss stays near $5.6 million while Xepi launch costs begin, Pelthos will need outside funding before its products break even.
Risks this quarter didn't answer
Three standing structural and financing risks received no operational update in the third-quarter press release.
- Single-product dependence: Zelsuvmi still generates 98.8% of total revenue until Xepi launches in the first quarter of 2027.
- European licensing deadline: the release said nothing about the September 30, 2026 European partnering milestone in the Ligand license agreement; the quarterly 10-Q filing will show whether the terms changed.
- Convertible note volatility and maturity: a non-cash $4.1 million fair-value gain lowered GAAP net loss to $7.9 million after a $3.7 million charge in the second quarter, and the November 2027 note maturity remains a dilution risk.
👓 Other Themes
Castle Creek Merger Adds Late-Stage Gene Therapy
On October 30, Pelthos agreed to combine with Castle Creek Biosciences, a private developer of gene therapies for rare skin disorders, in a deal set to close by the end of the first quarter of 2027. Plesha called it "a transaction that we believe will create a stronger, more diversified biotechnology company" and said Castle Creek's lead therapy, D-Fi, has "the potential to become a blockbuster franchise in dystrophic epidermolysis bullosa, or DEB".
💲 Other KPIs
Uncollected customer bills rose to $13.4 million at September 30, up 51.4% from $8.9 million at the end of 2025 and up from $11.7 million in the first quarter. By our math, receivables now equal 78 days of revenue, tying up working capital as pharmacy benefit coverage expands.
Overhead and sales-force spending fell 24.7% from $25.0 million in the second quarter, which included a one-time $5.3 million milestone charge. Excluding that one-off charge, underlying overhead dipped 4.7% from last quarter by our math and stayed near the $18.5 million spent in the fourth quarter of 2025.
Basic and diluted common shares rose 9.1% from the second quarter and 26.2% from a year ago. Including Series A and Series C convertible preferred stock, the biopharmaceutical company has 9.1 million shares on an as-converted basis, more than double the 3.9 million common shares issued at quarter-end.
🔮 Guidance
Unchanged. The drug maker still expects rebates to tick up slightly as its new 24-million-life pharmacy benefit contract takes effect, before net revenue per tube improves over time. By our math, realized net revenue per dispensed unit has already slipped for three straight quarters, falling 5.0% in the third quarter to $1,228.
Unchanged. Plesha reiterated the plan to relaunch Xepi, a prescription cream for impetigo, in the first quarter of 2027. The launch date had previously slipped three times from an original target of late 2025, so holding the first-quarter window keeps the second commercial product on schedule.
Unchanged. Management kept its target to launch Xeglyze, a topical treatment for head lice, in the third quarter of 2027. Both new skin treatments will run through the existing 67-territory dermatology sales force.
Unchanged. Pelthos said its $17.7 million in September cash plus the $10.0 million borrowed from Horizon in October will support its current business plan. Management has not stated whether that plan now includes funding Castle Creek's clinical trials after the merger closes in the first quarter of 2027.
❓ Key Questions
What will Castle Creek add to quarterly cash burn?
Pelthos burned $6.5 million of cash in the third quarter alone. The press release did not disclose Castle Creek's cash balance, debt, or the cost of running phase 3 trials for D-Fi, nor how much of the combined company Pelthos shareholders will own.
What was the exact third-quarter gross-to-net discount on Zelsuvmi?
Management disclosed the gross-to-net discount on prior calls (29.6% in the second quarter) but omitted the figure from the release. Because realized revenue per unit fell 5.0% to $1,228, investors need to know how much came from rebates versus pharmacy destocking.
Did Pelthos meet the September 30 European partnering deadline?
Under the Ligand royalty agreement, failing to make a commercially reasonable effort to sign a European partner by September 30, 2026 gives Ligand termination rights on the Zelsuvmi license. That date has now passed without an update.
Does the $6.2 million stockholders' deficit threaten the stock exchange listing?
Total liabilities of $135.0 million now exceed total assets of $128.8 million, widening the stockholders' deficit from $1.5 million in June to $6.2 million. Management has not said whether NYSE American requires a compliance plan.